Filters
Results 1 - 1 of 1
Results 1 - 1 of 1.
Search took: 0.018 seconds
AbstractAbstract
[en] Purpose: Whole-liver radiation, with or without chemotherapy, has been of modest benefit in the treatment of unresectable hepatic metastases from colorectal cancer. A Phase I/II study combining escalating doses of conformally planned radiation therapy (RT) with intraarterial hepatic (IAH) fluorodeoxyuridine (FdUrd) was performed. Methods and Materials: Twenty-two patients with unresectable hepatic metastases from colorectal cancer, 14 of whom had progressed after previous chemotherapy (2 with prior IAH FdUrd), were treated with concurrent IAH FdUrd (0.2 mg/kg/day) and conformal hepatic radiation therapy (1.5-1.65 Gy/fraction twice a day). The total dose of radiation given to the tumor (48-72.6 Gy) depended on the fraction of normal liver excluded from the high-dose volume. All patients were assessed for response, toxicity, hepatobiliary relapse, and survival. Median potential follow-up was 42 months. Results: Eleven of 22 patients demonstrated an objective response, with the remainder showing stable disease. Actuarial freedom from hepatic progression was 25% at 1 year. The most common acute toxicity was mild to moderate nausea and transient liver function test abnormalities. There were three patients with gastrointestinal bleeding (none requiring surgical intervention) after the completion of treatment. Overall median survival was 20 months. The presence of extrahepatic disease was associated with decreased survival (p < 0.01). Conclusions: Combined conformal radiation therapy and IAH FdUrd can produce an objective response in 50% of patients with hepatic metastases from colorectal cancer. However, response was not durable, and hepatic progression was frequent. Improvements in hepatic tumor control for patients with metastatic colorectal cancer may require higher doses of conformal radiation and/or improved radiosensitization. In an effort to increase radiosensitization, we have recently initiated a clinical trial combining IAH bromodeoxyuridine, a thymidine analog radiosensitizer, with conformal high dose radiation therapy
Primary Subject
Source
Copyright (c) 1995 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 32(2); p. 445-450

Country of publication
ANTI-INFECTIVE AGENTS, ANTIMETABOLITES, ANTIMICROBIAL AGENTS, AZINES, BIOLOGICAL EFFECTS, BODY, BROMOURACILS, DIGESTIVE SYSTEM, DISEASES, DOSES, DRUGS, FLUOROURACILS, GASTROINTESTINAL TRACT, GLANDS, HETEROCYCLIC COMPOUNDS, HYDROXY COMPOUNDS, INTESTINES, MEDICINE, NEOPLASMS, NUCLEAR MEDICINE, NUCLEOSIDES, NUCLEOTIDES, ORGANIC BROMINE COMPOUNDS, ORGANIC COMPOUNDS, ORGANIC FLUORINE COMPOUNDS, ORGANIC HALOGEN COMPOUNDS, ORGANIC NITROGEN COMPOUNDS, ORGANS, PYRIMIDINES, RADIATION EFFECTS, RADIOLOGY, RADIOSENSITIZERS, RESPONSE MODIFYING FACTORS, RIBOSIDES, THERAPY, URACILS
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue